News about Market

Navamedic Sees Over 48% YoY Growth in Antibiotics Sales Boosted by Tender Wins

During the second quarter, Navamedic’s Hospital business delivered strong growth, driven primarily by Nordic tender wins in its antibiotics portfolio.

Market | 14/08/2025 | By Dineshwori |  144

US Antibody Drug Conjugates Market projected to Surpass USD 11 billion by 2034

The growth of US antibody drug conjugates (ADCs) market is driven by the rising investments in ADC research and development for discovering and developing novel and targeted cancer therapies.

Market | 13/08/2025 | By Dineshwori |  132

Senores Pharmaceuticals to Acquire Two ANDAs from Teva in USD 120 Million Market Opportunity

Senores Pharmaceuticals (SPL), through its wholly-owned US subsidiary Senores Pharmaceuticals, USA (SPI), has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA.

Market | 13/08/2025 | By Darshana |  203

Abbott's US Diagnostics Sales Decline in Q2 Due to Falling COVID-19 Test Demand: GlobalData

Abbott Laboratories has continued to demonstrate steady performance in the US medical device market amid market shifts, though its diagnostics segment experienced a modest decline, according to new insights from GlobalData, a leading data and analytics firm.

Market | 12/08/2025 | By Dineshwori |  454

Medistep Healthcare to Launch INR 16.1 Crore SME IPO on August 8

Gujarat-based SME pharmaceutical products trader Medistep Healthcare will open its initial public offering (IPO) for subscription on 8 August, becoming the third company to launch an IPO on the same day, alongside ANB Metal Cast and Star Imaging & Path Lab. The offer will close on 12 August, with the issue price fixed at INR 43 per share.

Market | 11/08/2025 | By Darshana |  333

Boan Biotech's Dulaglutide Biosimilar 'Boyouping' Approved for Marketing in China

Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping (dulaglutide injection), indicated for glycemic control in adults with type 2 diabetes mellitus.

Market | 11/08/2025 | By Dineshwori |  577

Wockhardt Q1 Loss Widens to INR 108 Crore on US Subsidiary Liquidation

The loss was mainly driven by a INR 97 crore goodwill impairment following the company’s permanent exit from the US generics market and the voluntary liquidation of its Delaware-based subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.

Market | 11/08/2025 | By Darshana |  223

Biopharma and Healthcare Manufacturing Drive USD 18.3 Billion in Deals in July 2025 Despite Drop in Volume

While the number of deals was lower than the 12-month average of 95, the total deal value was significantly higher than the USD 13.2 billion average recorded between July 2024 and June 2025.

Market | 08/08/2025 | By Darshana |  225

Eli Lilly to Divest New Jersey Plant Amidst USD 27 Billion U.S. Manufacturing Expansion

As Eli Lilly advances its ambitious USD 27 billion investment plan to establish four new manufacturing facilities in the United States, the company has confirmed plans to sell its existing production site in Branchburg, New Jersey—a facility that has faced regulatory scrutiny in the past.

Market | 07/08/2025 | By Darshana |  598

Novo Nordisk Reports 18% H1 Sales Growth, Lowers H2 Outlook for Wegovy and Ozempic

Novo Nordisk has announced its financial results for the first half of 2025, ending June 30, with sales rising 18 percent at constant exchange rates (CER) to DKK 154.9 billion (USD 24.78 billion).

Market | 06/08/2025 | By Dineshwori |  1797